Oncopeptides AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 2.81 million. Net loss was SEK 40.54 million compared to SEK 88.44 million a year ago. Basic loss per share from continuing operations was SEK 0.45 compared to SEK 1 a year ago.
For the nine months, sales was SEK 29.88 million compared to SEK 7.8 million a year ago. Net loss was SEK 167.9 million compared to SEK 246.85 million a year ago. Basic loss per share from continuing operations was SEK 1.86 compared to SEK 3.1 a year ago.